The experimental drug abiraterone, which prevents testosterone production anywhere in the body, may reduce blood levels of the prostate cancer marker prostate-specific antigen (PSA) by half, new research shows.
The study also found that the drug can shrink tumors in men whose prostate cancer has continued to grow despite treatment.
Leave a Reply